Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.

Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.

Item
http://www.wikidata.org/entity/Q33981554
In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibioticMoxifloxacin dosing in post-bariatric surgery patients.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin in Pig against Korean Local Isolates of Actinobacillus pleuropneumoniae.Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.Trends in antibiotic resistance in bacterial keratitis isolates from South India.Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge systemFactors influencing fluoroquinolone resistance.Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection.In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin.Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination.Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin after intravenous and intramuscular administration in beagle dogs.
P2860

Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.

Item
http://www.wikidata.org/entity/Q33981554
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Comparative bactericidal activ ...... e in a dynamic in vitro model.
@ast
Comparative bactericidal activ ...... e in a dynamic in vitro model.
@en
type
label
Comparative bactericidal activ ...... e in a dynamic in vitro model.
@ast
Comparative bactericidal activ ...... e in a dynamic in vitro model.
@en
prefLabel
Comparative bactericidal activ ...... e in a dynamic in vitro model.
@ast
Comparative bactericidal activ ...... e in a dynamic in vitro model.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Comparative bactericidal activ ...... ae in a dynamic in vitro model
@en
P2093
P2860
P304
P31
P356
10.1128/AAC.45.3.673-678.2001
P407
P433
P478
P50
P577
P698
P932